Project Grant HT94252310246
Award Date 4/1/23
Completion Date 3/31/26
Dollars Obligated $5.6M
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Madison, WI 53711, USA
Similar Awards
- The Defense Health Agency awarded Flugen Inc. a $6,237,445 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to optimize downstream recovery and stabilization of the drug substance for their intranasal influenza vaccine. The three-year grant also supports research on concurrent administration of Flugen's H3N2 M2SR monovalent influenza vaccine with inactivated flu vaccines in older adult populations. This award builds on Flugen's previous federal grants...
- This $854,060 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) was provided to Formation Venture Engineering Foundry Inc., a for-profit biotech firm, to develop an FC-fusion protein active vaccine for the prevention and treatment of C9ORF72 ALS/FTD, a rare neurodegenerative disease. The award period is from Apr 15, 2024 to Apr 14, 2026. The Military Medical Research and Development program supports innovative biomedical research...
- This Project Grant from the Defense Health Agency provides $734,781 to Formation Venture Engineering Foundry Inc. for precision medicine immunotherapy research under the Military Medical Research and Development program (CFDA 12.420). The research aims to develop medical solutions for treating neurodegeneration in amyotrophic lateral sclerosis patients who test positive for human endogenous retrovirus K. The awardee will conduct applied and advanced biomedical research from June 2023 through...
- This Cooperative Agreement award of $638,820 from the Defense Health Agency supports an mRNA multivalent approach to develop an innovative malaria vaccine. The project, funded through the Military Medical Research and Development program (CFDA 12.420), aims to broaden the immune targets against malaria infection by including both pre-erythrocytic-stage antigens and mosquito saliva antigens. The Geneva Foundation, a non-profit research organization, will conduct this research over a 3-year period...
- The Project Grant award for $897,448.00, awarded on June 1, 2024 by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports Oregon Health & Science University's development of "NEXT-GENERATION ELQS FOR LONG-TERM PROTECTION AGAINST MALARIA." This research initiative aims to advance novel treatments and protective measures against malaria, a key focus area for the Defense Health Agency's military medical research initiatives....
- The federal Project Grant award of $1,214,375.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), is funding a research project led by Yale University. The project is investigating the use of decoy-resistant IL-18 and immune checkpoint inhibitors in preclinical murine and ex vivo patient-derived models of renal cell carcinoma. The award began on September 15, 2024 and is set to conclude on September 14, 2028. The Military Medical Research...
- The Defense Health Agency awarded a $299,991 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Feinstein Institutes For Medical Research, located in Plandome, NY. The grant, with an award date of October 1, 2025 and an ultimate completion date of September 30, 2027, will support research on the "Proinflammatory Function and Heterogeneity of Age-Associated B Cells in SLE." As a non-profit medical research organization, The Feinstein...
- This $487,407 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by Factor Bioscience Inc. in East Cambridge, MA. The objective is to develop iPSC-derived mesenchymal stromal cells expressing a novel TNF inhibitor for the treatment of rheumatoid arthritis. This 1-year project, running from August 1, 2025 to July 31, 2026, aims to advance innovative biomedical solutions to address critical health...
- This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the development of a measles-vectored cytomegalovirus vaccine that induces both neutralizing and non-neutralizing antibodies. The $429,000 award was granted to Thomas Jefferson University, doing business as Sidney Kimmel Medical College, a leading academic medical research institution. The research project aims to transform healthcare for military service members,...
- This Project Grant award for $373,470.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by Flashpoint Therapeutics, Inc. to develop LNP-based small nucleic acid (SNA) therapies to overcome immunosuppression in glioblastoma. The research, conducted in Palo Alto, CA, aims to transform healthcare for military service members, veterans, and the broader public by advancing innovative medical solutions to address critical health...